€ million |
|
Note |
|
2020 |
|
2019 |
|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
1,994 |
|
1,324 |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Net defined benefit liability |
|
|
|
|
|
|
Changes in remeasurement |
|
|
|
-602 |
|
-488 |
Tax effect |
|
|
|
130 |
|
100 |
Changes recognized in equity |
|
|
|
-473 |
|
-388 |
Equity instruments |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
116 |
|
76 |
Tax effect |
|
|
|
– |
|
– |
Changes recognized in equity |
|
|
|
116 |
|
76 |
|
|
|
|
-356 |
|
-312 |
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
|
|
Cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
54 |
|
-15 |
Reclassification to profit or loss |
|
|
|
45 |
|
-20 |
Reclassification to assets |
|
|
|
– |
|
60 |
Tax effect |
|
|
|
-30 |
|
-16 |
Changes recognized in equity |
|
|
|
69 |
|
9 |
Cost of cash flow hedge reserve |
|
|
|
|
|
|
Fair value adjustments |
|
|
|
-13 |
|
11 |
Reclassification to profit or loss |
|
|
|
12 |
|
-8 |
Reclassification to assets |
|
|
|
– |
|
21 |
Tax effect |
|
|
|
1 |
|
-24 |
Changes recognized in equity |
|
|
|
-1 |
|
– |
Currency translation difference |
|
|
|
|
|
|
Changes taken directly to equity |
|
|
|
-1,864 |
|
349 |
Reclassification to profit or loss |
|
|
|
4 |
|
-6 |
Changes recognized in equity |
|
|
|
-1,860 |
|
344 |
|
|
|
|
-1,792 |
|
353 |
Other comprehensive income |
|
|
|
-2,149 |
|
41 |
Comprehensive income |
|
|
|
-155 |
|
1,365 |
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
-160 |
|
1,359 |
thereof: attributable to non-controlling interests |
|
|
5 |
|
6 |
|
|
|
|
|
|
|
|
Comprehensive income |
|
|
|
-155 |
|
1,365 |
thereof: from continuing operations |
|
|
|
-155 |
|
1,337 |
thereof: from discontinued operation |
|
|
|
– |
|
28 |
TAG overview
Results
- Please select a #tag from the overview (see above).
- To Our Shareholders
- Letter from Stefan Oschmann
- The Executive Board
- Our Shares
- In figures
- Management Report
- Fundamental Information about the Group
- The Group
- Our contributions to combating Covid-19
- Healthcare
- Life Science
- Performance Materials
- Strategy*
- Strategy Fundamentals
- Group Strategy
- Business Strategies
- Sustainability Strategy
- Strategic finance and dividend policy
- Internal Management System
- Key performance indicators
- Investments and value management
- Capital market-related parameters
- Other relevant/non-financial performance measures
- Sustainability*
- Innovations and technology
- Contribution of our technologies
- Sustainability culture and values
- Supply chain
- Social license
- Climate change and emissions
- Water and resource intensity
- Research and Development
- Healthcare*
- Life Science*
- Performance Materials*
- People*
- Leadership
- Talent
- Diversity and dialogue
- Differentiated solutions
- Report on Economic Position
- Macroeconomic Environment
- Review Forecast against Business Developments
- Course of Business and Economic Position
- Group
- Healthcare
- Life Science
- Performance Materials
- Corporate and Other
- Report on Risks and Opportunities
- Business-related risks and opportunities
- Financial risks and opportunities
- Legal risks
- Human resources risks
- Information technology risks
- Environmental, climate related and safety risks
- Risks due to the divestment, acquisition, and integration of companies and businesses
- Management assessment
- Report on Expected Developments
- Report in accordance with section 315 (4) of the German Commercial Code (HGB)
- Additional Information in accordance with the German Commercial Code (HGB)
- Corporate Governance
- Capital Structure and Corporate Bodies
- Statement on Corporate Governance
- Compensation Report
- Corporate governance practices
- Procedures of the Executive Board, Supervisory Board, Board of Partners, and its Committees
- Promote women in management positions
- Diversity policy
- Report of the Supervisory Board
- Objectives of the Supervisory Board
- Consolidated Financial Statements
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet
- Cash Flow Statement
- Statement of Changes in Net Equity
- Notes
- General Disclosures
- (1) Company information
- (2) Reporting principles
- (3) Discretionary decisions and sources of estimation uncertainty
- (4) Subsequent events
- Group Structure
- (5) Changes in the scope of consolidation
- (6) Acquisitions and divestments
- (7) Collaboration and licensing agreements
- Operating Activities
- (8) Segment Reporting
- (9) Net sales
- (10) Cost of sales
- (11) Marketing and selling expenses
- (12) Research and development costs
- (13) Other operating income
- (14) Other operating expenses
- (15) Income tax
- (16) Net cash flows from operating activities
- (17) Earnings per share
- Operating Assets, Liabilities and Contingent Liabilities
- (18) Goodwill
- (19) Other intangible assets
- (20) Property, plant and equipment
- (21) Leasing
- (22) Other non-financial assets
- (23) Net cash flows from investing activities
- (24) Inventories
- (25) Trade and other receivables
- (26) Contract assets
- (27) Other provisions
- (28) Contingent liabilities
- (29) Other non-financial liabilities
- (30) Trade and other payables
- Employees
- (31) Number of employees
- (32) Personnel expenses
- (33) Provisions for employee benefits
- Capital Structure, Investments and Financing Activities
- (34) Equity
- (35) Cash and cash equivalents
- (36) Other financial assets
- (37) Financial debt/capital management
- (38) Other financial liabilities
- (39) Derivative financial instruments
- (40) Finance income and expenses/Net gains and losses from financial instruments
- (41) Net cash flows from financing activities
- (42) Management of financial risks
- (43) Information on fair value measurement
- (44) Other financial obligations
- Other Disclosures
- (45) Related party disclosures
- (46) Executive Board and Supervisory Board compensation
- (47) Auditor's fees
- (48) Corporate governance
- (49) Information on preparation and approval
- Scope of Consolidation
- (50) List of shareholdings
- Other Information
- Responsibility Statement
- Reproduction of the Independent Auditor's Report
- Business Development 2016 – 2020
- Financial Calendar